In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing. Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
Study Type
OBSERVATIONAL
Enrollment
20
Medical University of Vienna
Vienna, Vienna, Austria
RECRUITINGKlinikum rechts der Isar, School of Medicine, Technical University of Munich
Munich, Bavaria, Germany
ACTIVE_NOT_RECRUITINGCharité - Universitätsmedizin Berlin
Berlin, State of Berlin, Germany
RECRUITINGMetabolomics
Blood Metabolome will be isolated from blood samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) using mass spectrometry.
Time frame: a median of 14 days
Muscle histology
Immunohistochemistry will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Time frame: a median of 14 days
Phosphoproteomics
Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Time frame: a median of 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.